Tyra Biosciences, Inc. Increase (Decrease) in Prepaid Expenses, Other
Tyra Biosciences, Inc. (TYRA) reported Increase (Decrease) in Prepaid Expenses, Other of $3.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2026-08-04
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2026-06-30 was $1.02M, a 9.70% increase year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2026-03-31 was $2.44M, a 8.59% decline year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2025-12-31 was -$404.00K, a 121.12% decline year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2025-09-30 was $1.89M, a 6.30% decline year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for fiscal 2025 was $5.08M, a 2905.92% increase from fiscal 2024.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for fiscal 2024 was $169.00K, a 94.01% decline from fiscal 2023.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for fiscal 2023 was $2.82M, a 65.73% decline from fiscal 2022.
- Tyra Biosciences, Inc. increase (decrease) in prepaid expenses, other for fiscal 2022 was $8.24M, a 290.80% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 3 month | Increase (Decrease) in Prepaid Expenses, Other 6 month | Increase (Decrease) in Prepaid Expenses, Other 6 month as first filed | Increase (Decrease) in Prepaid Expenses, Other 9 month | Increase (Decrease) in Prepaid Expenses, Other 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.46M 10-Q · filed 2026-08-04 | $3.05M derived: sum of 3 quarters · filed 2026-08-04 | $4.94M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $2.44M 10-Q · filed 2026-05-13 | $2.03M derived: sum of 2 quarters · filed 2026-05-13 | $3.92M derived: sum of 3 quarters · filed 2026-05-13 | $4.85M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.49M derived: sum of 2 quarters · filed 2026-03-02 | $2.41M derived: sum of 3 quarters · filed 2026-08-04 | $5.08M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.82M derived: sum of 2 quarters · filed 2026-08-04 | $5.48M 10-Q · filed 2025-11-05 | $7.40M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $928.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.60M 10-Q · filed 2026-08-04 | $5.51M derived: sum of 3 quarters · filed 2026-08-04 | $7.52M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $2.67M 10-Q · filed 2026-05-13 | $4.58M derived: sum of 2 quarters · filed 2026-05-13 | $6.60M derived: sum of 3 quarters · filed 2026-05-13 | $2.79M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.93M derived: sum of 2 quarters · filed 2026-03-02 | $126.00K derived: sum of 3 quarters · filed 2026-03-02 | $169.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.79M derived: sum of 2 quarters · filed 2025-11-05 | -$1.74M 10-Q · filed 2025-11-05 | -$2.83M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.76M 10-Q · filed 2025-08-14 | -$4.85M derived: sum of 3 quarters · filed 2025-08-14 | $400.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $43.00K 10-Q · filed 2025-05-08 | -$1.04M derived: sum of 2 quarters · filed 2025-05-08 | $4.20M derived: sum of 3 quarters · filed 2025-05-08 | $4.40M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.16M derived: sum of 2 quarters · filed 2025-03-27 | $4.35M derived: sum of 3 quarters · filed 2025-03-27 | $2.82M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.44M derived: sum of 2 quarters · filed 2024-11-07 | $3.91M 10-Q · filed 2024-11-07 | $6.20M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$1.34M 10-Q · filed 2024-08-07 | $956.00K derived: sum of 3 quarters · filed 2024-08-07 | $1.82M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | -$1.53M 10-Q · filed 2024-05-09 | $763.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.63M derived: sum of 3 quarters · filed 2024-05-09 | $7.01M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.15M derived: sum of 2 quarters · filed 2024-03-19 | $8.54M derived: sum of 3 quarters · filed 2024-03-19 | $8.24M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $862.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $6.24M derived: sum of 2 quarters · filed 2023-11-07 | $5.95M 10-Q · filed 2023-11-07 | $7.14M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.08M 10-Q · filed 2023-08-10 | -$5.08M 10-Q · filed 2022-08-04 | $6.27M derived: sum of 3 quarters · filed 2023-08-10 | $7.04M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$299.00K 10-Q · filed 2023-05-04 | $892.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.65M derived: sum of 3 quarters · filed 2023-05-04 | $1.72M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.95M derived: sum of 2 quarters · filed 2023-03-22 | $2.02M derived: sum of 3 quarters · filed 2023-03-22 | $2.11M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $826.00K derived: sum of 2 quarters · filed 2022-11-03 | $917.00K 10-Q · filed 2022-11-03 | $870.00K derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $156.00K 10-Q · filed 2022-08-04 | $109.00K derived: sum of 3 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $91.00K 10-Q · filed 2022-05-05 | $44.00K derived: sum of 2 quarters · filed 2022-05-05 | |||
| 2020-12-31 | -$47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$65.00K 10-K · filed 2022-03-03 | |||
| 2020-09-30 | -$18.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |